Is REPL or RIGL more undervalued in 2026?

CirclFi compares Replimune Group, Inc. (REPL) and Rigel Pharmaceuticals, Inc. (RIGL) using 13 institutional-grade valuation models. REPL has a Quality of Company score of 4.4/10 while RIGL scores 9.1/10.

Which is a better buy — REPL or RIGL?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do REPL and RIGL valuations compare?

REPL at $4.68 and RIGL at $30.05 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

REPL vs RIGL Valuation Comparison 2026 — Intrinsic Value Analysis

REPL

Biotechnology

Replimune Group, Inc.

Quality

4.4

out of 10

Value Trap

SAFE

Price

$4.68

Last close

Models

7/13

Active

RIGL

Biotechnology

Rigel Pharmaceuticals, Inc.

Quality

9.1

out of 10

Value Trap

SAFE

Price

$30.05

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	REPL Fair Value	REPL Upside	RIGL Fair Value	RIGL Upside
Bayesian DCF	Intrinsic	$1.65	-64.7%	$21.03	-30.0%
Earnings Power Value	Intrinsic	—	—	$50.82	+69.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$2.21	-52.7%	$65.74	+118.8%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for REPL vs RIGL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

REPL vs RIGL — Which Stock Is More Undervalued?

RIGL scores higher with a 9.1/10 quality rating vs REPL's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Replimune Group, Inc. (REPL) and Rigel Pharmaceuticals, Inc. (RIGL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

REPL currently trades at $4.68 with a QOC of 4.4/10, while RIGL trades at $30.05 with a QOC of 9.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).